Published in Am J Epidemiol on October 24, 2011
A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med (2013) 2.00
Causal inference, probability theory, and graphical insights. Stat Med (2013) 1.69
Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes (2013) 1.62
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med (2015) 1.57
Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf (2012) 1.32
Invited commentary: understanding bias amplification. Am J Epidemiol (2011) 1.29
High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. Eur J Clin Pharmacol (2012) 1.09
Combining directed acyclic graphs and the change-in-estimate procedure as a novel approach to adjustment-variable selection in epidemiology. BMC Med Res Methodol (2012) 1.09
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med (2014) 1.06
Ambient air pollution and traffic exposures and congenital heart defects in the San Joaquin Valley of California. Paediatr Perinat Epidemiol (2013) 1.02
On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study. Stat Med (2013) 0.99
A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf (2013) 0.95
The role of prediction modeling in propensity score estimation: an evaluation of logistic regression, bCART, and the covariate-balancing propensity score. Am J Epidemiol (2014) 0.92
Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf (2012) 0.88
Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf (2012) 0.85
Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. Int J Epidemiol (2016) 0.82
Problem drinking as a risk factor for tuberculosis: a propensity score matched analysis of a national survey. BMC Public Health (2013) 0.81
Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders. Alcohol Clin Exp Res (2015) 0.80
Evaluating possible confounding by prescriber in comparative effectiveness research. Epidemiology (2015) 0.80
Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score. J Causal Inference (2014) 0.80
Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. Pharmacoepidemiol Drug Saf (2014) 0.79
Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiol Drug Saf (2014) 0.77
Commentary: Balancing automated procedures for confounding control with background knowledge. Epidemiology (2014) 0.77
A simulation study on matched case-control designs in the perspective of causal diagrams. BMC Med Res Methodol (2016) 0.75
Outcome-wide Epidemiology. Epidemiology (2017) 0.75
The ACCE method: an approach for obtaining quantitative or qualitative estimates of residual confounding. F1000Res (2014) 0.75
Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study. BMC Psychiatry (2014) 0.75
Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy. Paediatr Perinat Epidemiol (2016) 0.75
Diagnostics for Confounding of Time-varying and Other Joint Exposures. Epidemiology (2016) 0.75
Model Misspecification When Excluding Instrumental Variables From PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. Epidemiol Method (2014) 0.75
Instrumental variables as bias amplifiers with general outcome and confounding. Biometrika (2017) 0.75
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med (2007) 9.89
Instruments for causal inference: an epidemiologist's dream? Epidemiology (2006) 8.50
Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf (2004) 7.55
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
Matching using estimated propensity scores: relating theory to practice. Biometrics (1996) 6.73
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med (2007) 6.48
The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics (1968) 5.54
Estimating treatment effects using observational data. JAMA (2007) 4.12
Instrumental variables: application and limitations. Epidemiology (2006) 3.03
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med (2008) 2.76
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf (2011) 1.74
Bayesian propensity score analysis for observational data. Stat Med (2009) 1.39
Propensity scores and M-structures. Stat Med (2009) 1.27
The efficiency of matched samples: an empirical investigation. Biometrics (1965) 1.01
Using observational data to estimate treatment effects. JAMA (2007) 0.88
Analytic approaches to observational studies with treatment selection bias. JAMA (2007) 0.86
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
The rise and fall of epidemiology, 1950-2000 A.D. 1981. Int J Epidemiol (2007) 4.56
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
Causal mediation analyses with rank preserving models. Biometrics (2007) 2.67
Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol (2014) 2.67
Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol (2006) 2.65
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J (2007) 2.55
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics (2003) 2.49
Statin adherence and risk of accidents: a cautionary tale. Circulation (2009) 2.47
Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis (2008) 2.43
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2012) 2.42
Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf (2008) 2.42
Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med (2013) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf (2006) 2.38
Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med (2006) 2.36
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation (2009) 2.26
Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat (2007) 2.24
Rates of completion of the medical evaluation for renal transplantation. Am J Kidney Dis (2005) 2.22
A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Arch Intern Med (2007) 2.20
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol (2012) 2.14